Microvascular Angina Clinical Trial
Official title:
Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction and No Obstructive Coronary Artery Disease
Verified date | February 2017 |
Source | Bispebjerg Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to explore effects of long term treatment with ACE-inhibitor on the small vessel function assessed by coronary flow reserve (CFR) by transthoracic echocardiography and flow mediated dilation in normotensive patients with small vessel disease (CFR<2.2) and Angina Pectoris but no obstructive coronary artery disease.
Status | Completed |
Enrollment | 63 |
Est. completion date | July 2016 |
Est. primary completion date | July 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 86 Years |
Eligibility |
Inclusion Criteria: - Patients from an established cohort of patients with non obstructive coronary artery disease - Microvascular dysfunction defined as a transthoracic echocardiography measured coronary flow reserve (CFR) < 2.2 - A good quality (quality index > 3) examination - A blood pressure = 150 at last visit in iPower - Patients who are not in treatment for documented hypertension Exclusion Criteria: - Current treatment with ACE-inhibitors or Angiotensin II-antagonists - Atrial fibrillation - Pace-maker - Allergy towards Ace-inhibitor, Ramipril ® or tool-medicine: Dipyridamole/adenosine, Nitro-glycerine or rescue medicine: Theophylline - Baseline CFR >2.5 when entering ACIM-study. - No episodes of chest pain within 6 months before inclusion - Coronary angiography with significant stenotic lesions (>/=50%) - Other cause of chest discomfort deemed highly likely - Left ventricular ejection fraction below 45% assessed by echocardiography at baseline measurement - Significant valvular heart disease (Definition: Verified in medical records after echocardiography. If the echocardiographer in this study suspects valvular heart disease, the patient is referred for expert evaluation and excluded from the study until valvular disease has been excluded. All definitions are taken from the guidelines of the Danish Society of Cardiology (DCS). - Haemodynamic significant Aortic Stenosis: Valve area < 1 cm2 or <0.6 cm2/m2 body surface area. - Severe aorta Regurgitation (AR): Vena contracta > 6 mm, Moderate/severe left ventricle (LV) volume load, ERO > 0.3 cm². - Mitral Stenosis (MS): Valve area < 2.5 cm2. - Severe Mitral Regurgitation (MR): effective regurgitant orifice > 0.4 cm², Moderate/severe LV-load, Vena contracta > 6 mm. - Congenital heart disease or cardiomyopathy verified in medical records - Significant co-morbidity with < 1 year expected survival: decision made by the person responsible for inclusion based on the patient interview and/or medical records. - Severe chronic obstructive pulmonary disease with forced expiratory volume in 1 second (FEV1)<50% of predicted - Severe asthma defined as asthma which requires treatment with high dose inhaled corticosteroids (ICS) plus a second controller (long acting ß2 agonist (LABA), leukotriene modifier, theophylline or systemic corticosteroids) to prevent it from becoming uncontrolled or which remains uncontrolled despite this therapy." - Previous verified myocardial infarction (Definition: verified in medical records, ST segment elevation myocardial infarction (STEMI) (ST segment elevation, elevated enzymes) or non-ST-segment elevation myocardial infarction (NSTEMI) (elevated enzymes, ECG changes/no ECG changes). - Previous revascularization (Percutaneous Coronary Intervention or coronary artery bypass grafting) - Elevated cardiac biomarkers: Troponin > 50 ng/l (high sensitive) or > 0.03 µg/l (4. generation), creatinin kinase myoglobin (CKMB) > 4.0 µg/l (women). - ECG with verified ST-segment elevation - Language- or other barrier to giving informed consent (for example mental ability to understand project) - Travel distance: a distance to research hospital requiring more than 3 hours of travel - Patient unwilling to participate (Low burden of symptoms, other illnesses, "Lack of energy", transport problems, anxiety because of the examination, other). - No signed informed consent. - Other (Pregnancy, significant psychiatric disorder) - glomerular filtration rate < 50 mL/min/1,73 m2 |
Country | Name | City | State |
---|---|---|---|
Denmark | Bispebjerg Hospital | Copenhagen NV |
Lead Sponsor | Collaborator |
---|---|
Bispebjerg Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in coronary flow reserve to after intervention | Coronary flow reserve is assessed by non-invasive Trans-Thoracic Doppler Echocardiography (TTDE) | Patients are followed on average 6 months | |
Secondary | Change from baseline in Seattle Angina Questionnaire to after intervention | Evaluated by validated questionnaires: Seattle Angina Questionnaire | Patients are followed on average 6 months | |
Secondary | Change from baseline in Endothelial function to after intervention | Endothelial function is assessed by flow mediated dilation of the brachial artery by ultrasound | Patients are followed on average 6 months | |
Secondary | Change from baseline in Systolic function by speckle tracking strain to after intervention | strain assessed by speckle tracking echocardiography | Patients are followed on average 6 months | |
Secondary | Change from baseline in Roses questionnaire to after intervention | Evaluated by validated questionnaires: Roses Questionnaire | Patients are followed on average 6 months | |
Secondary | Change from baseline in Vital exhaustion questionnaire to after intervention | Evaluated by validated questionnaires: Vital exhaustion questionnaire | Patients are followed on average 6 months | |
Secondary | Change from baseline in International physical activity questionnaire (IPAQ) questionnaire to after intervention | Evaluated by validated questionnaires: IPAQ questionnaire | Patients are followed on average 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02147067 -
Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)
|
Phase 2 | |
Completed |
NCT06306066 -
Coronary Thermo-dilution Derived Flow-indices in Chronic Coronary Syndrome
|
||
Recruiting |
NCT05288361 -
The DISCOVER INOCA Prospective Multi-center Registry
|
||
Active, not recruiting |
NCT04777045 -
Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial
|
Phase 3 | |
Completed |
NCT04097314 -
Precision Medicine With Zibotentan in Microvascular Angina
|
Phase 2 | |
Recruiting |
NCT06025994 -
Standardizing the Management of Patients With Coronary Microvascular Dysfunction
|
N/A | |
Recruiting |
NCT04598308 -
EUROpean Coronary microCirculatory Resistance and Absolute Flow Trial
|
||
Completed |
NCT03193294 -
CORonary MICrovascular Angina (CorMicA)
|
N/A | |
Not yet recruiting |
NCT02284048 -
Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina
|
Phase 4 | |
Recruiting |
NCT00921856 -
Abnormal Coronary Vasomotion in Patients With Suspected Coronary Artery Disease (CAD)
|
N/A | |
Completed |
NCT02602600 -
Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis
|
Phase 4 | |
Recruiting |
NCT06070662 -
Non-invasive Diagnosis of Coronary Microvascular Disease: Pilot Study
|
||
Terminated |
NCT02914834 -
Acupuncture for Individuals With Stable Angina
|
N/A | |
Completed |
NCT04508998 -
PRIZE ET Sub-Study
|
N/A | |
Recruiting |
NCT05294887 -
Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT02095964 -
HDL-C in Cardiac Syndrome X
|
N/A | |
Recruiting |
NCT06401291 -
Transcutaneous Electrical Nerve Stimulation in Patients With Angina and Non-Obstructive Coronary Arteries
|
N/A | |
Completed |
NCT04391491 -
Neuregulin-1 in Patient With Different Forms of Cardiovascular Diseases: a Pilot Study
|
||
Recruiting |
NCT05635994 -
Advanced Invasive Diagnosis for Patients With Chronic Coronary Syndromes Undergoing Coronary ANGIOgraphy (AID-ANGIO)
|
||
Recruiting |
NCT05313919 -
Coronary Microcirculatory Disease and Inflammation in Patients With Chronic Coronary Syndrome and no Significant Coronary Artery Stenosis
|